Phaseline

Targets › CHRN

CHRN: drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 1; Metabolic and endocrine, Other.

Open in Phaseline: the race on CHRN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Yonsei UniversityChonline Alphoscerate
Cholinergic neuroprotective agent; precursor to phosphatidylcholine
CHRNPhase 4Type2 Diabetes With Depressive Mood–
Universitas PadjadjaranSugammadex
Selective relaxant binding agent that directly encapsulates and inactivates rocuronium
CHRNPhase 1Neuromuscular Blocking Agents–

Conditions

Type2 Diabetes With Depressive Mood (1) Neuromuscular Blocking Agents (1)

Modalities

small molecule (2)

Companies

Yonsei University (1) Universitas Padjadjaran (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.